 Eric Poeschla
Concepts (526)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunodeficiency Virus, Feline | 30 | 2023 | 34 | 6.890 |
Why?
| | HIV-1 | 39 | 2022 | 905 | 4.350 |
Why?
| | Genetic Vectors | 28 | 2013 | 335 | 3.980 |
Why?
| | Virus Integration | 20 | 2022 | 69 | 2.750 |
Why?
| | RNA, Viral | 14 | 2025 | 693 | 2.550 |
Why?
| | HIV Integrase | 14 | 2022 | 74 | 2.440 |
Why?
| | Virus Replication | 28 | 2022 | 527 | 2.340 |
Why?
| | Cats | 26 | 2023 | 228 | 2.000 |
Why?
| | Intercellular Signaling Peptides and Proteins | 14 | 2022 | 376 | 1.980 |
Why?
| | Lentiviruses, Primate | 4 | 2023 | 12 | 1.800 |
Why?
| | Lentivirus | 12 | 2022 | 61 | 1.760 |
Why?
| | Interferons | 3 | 2025 | 186 | 1.550 |
Why?
| | DNA, Viral | 8 | 2022 | 357 | 1.530 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 3 | 2025 | 19 | 1.480 |
Why?
| | Genetic Therapy | 13 | 2013 | 316 | 1.350 |
Why?
| | Cell Line | 36 | 2020 | 2823 | 1.340 |
Why?
| | Immunity, Innate | 7 | 2020 | 846 | 1.310 |
Why?
| | Picornaviridae | 3 | 2020 | 18 | 1.280 |
Why?
| | Chromatin | 9 | 2016 | 555 | 1.180 |
Why?
| | Reverse Transcription | 4 | 2021 | 20 | 1.070 |
Why?
| | RNA, Double-Stranded | 2 | 2025 | 56 | 1.030 |
Why?
| | RNA-Binding Proteins | 3 | 2025 | 461 | 1.000 |
Why?
| | Trabecular Meshwork | 9 | 2014 | 74 | 0.960 |
Why?
| | Antibodies, Viral | 2 | 2020 | 673 | 0.950 |
Why?
| | RNA Interference | 8 | 2020 | 473 | 0.940 |
Why?
| | Lentivirus Infections | 4 | 2014 | 9 | 0.930 |
Why?
| | Retroviridae | 5 | 2022 | 101 | 0.910 |
Why?
| | RNA Editing | 1 | 2025 | 26 | 0.900 |
Why?
| | Haploinsufficiency | 1 | 2025 | 54 | 0.890 |
Why?
| | Aqueous Humor | 7 | 2009 | 38 | 0.890 |
Why?
| | Gene Products, gag | 3 | 2012 | 38 | 0.880 |
Why?
| | Adenosine Deaminase | 1 | 2025 | 43 | 0.880 |
Why?
| | Gene Transfer Techniques | 10 | 2011 | 186 | 0.870 |
Why?
| | Adaptor Proteins, Signal Transducing | 7 | 2020 | 426 | 0.860 |
Why?
| | Virion | 7 | 2022 | 111 | 0.820 |
Why?
| | Virus Assembly | 6 | 2014 | 81 | 0.820 |
Why?
| | Integrases | 5 | 2022 | 123 | 0.800 |
Why?
| | HIV Infections | 15 | 2022 | 3189 | 0.790 |
Why?
| | Animals | 60 | 2025 | 38141 | 0.740 |
Why?
| | Transgenes | 8 | 2009 | 191 | 0.710 |
Why?
| | Capsid | 7 | 2022 | 93 | 0.710 |
Why?
| | Host-Pathogen Interactions | 6 | 2021 | 369 | 0.690 |
Why?
| | Molecular Sequence Data | 19 | 2014 | 2910 | 0.660 |
Why?
| | Gammaretrovirus | 1 | 2020 | 2 | 0.650 |
Why?
| | Spumavirus | 1 | 2020 | 3 | 0.650 |
Why?
| | Recombinant Fusion Proteins | 6 | 2011 | 667 | 0.630 |
Why?
| | Teicoplanin | 1 | 2020 | 14 | 0.620 |
Why?
| | HIV | 6 | 2012 | 252 | 0.610 |
Why?
| | Chiroptera | 1 | 2020 | 62 | 0.610 |
Why?
| | Prisons | 1 | 2020 | 85 | 0.600 |
Why?
| | Transcription Factors | 7 | 2020 | 1733 | 0.590 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 71 | 0.590 |
Why?
| | Fascioliasis | 1 | 2019 | 3 | 0.590 |
Why?
| | Liver Diseases, Parasitic | 1 | 2019 | 2 | 0.590 |
Why?
| | Humans | 99 | 2025 | 145491 | 0.570 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 342 | 0.570 |
Why?
| | Exodeoxyribonucleases | 1 | 2018 | 23 | 0.550 |
Why?
| | Nucleotidyltransferases | 1 | 2018 | 29 | 0.550 |
Why?
| | Retroviridae Infections | 3 | 2020 | 47 | 0.550 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 389 | 0.550 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.550 |
Why?
| | Amino Acid Sequence | 10 | 2023 | 2137 | 0.540 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2014 | 1138 | 0.530 |
Why?
| | Ferrets | 2 | 2020 | 31 | 0.510 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.510 |
Why?
| | Dyspnea | 1 | 2019 | 250 | 0.500 |
Why?
| | Transformation, Genetic | 2 | 2012 | 14 | 0.500 |
Why?
| | Eosinophilia | 1 | 2019 | 223 | 0.490 |
Why?
| | Outpatients | 1 | 2020 | 447 | 0.480 |
Why?
| | Phosphoproteins | 1 | 2018 | 339 | 0.470 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 4 | 2020 | 28 | 0.460 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2020 | 40 | 0.440 |
Why?
| | Viral Load | 3 | 2020 | 528 | 0.440 |
Why?
| | Antibodies, Monoclonal | 2 | 2020 | 1511 | 0.430 |
Why?
| | Pandemics | 2 | 2020 | 1706 | 0.430 |
Why?
| | Gene Knockout Techniques | 2 | 2014 | 117 | 0.420 |
Why?
| | DNA, Complementary | 2 | 2013 | 273 | 0.420 |
Why?
| | Cat Diseases | 1 | 2014 | 25 | 0.410 |
Why?
| | Cytosine Deaminase | 2 | 2010 | 15 | 0.400 |
Why?
| | HIV Integrase Inhibitors | 4 | 2022 | 79 | 0.390 |
Why?
| | Mice | 20 | 2025 | 18338 | 0.390 |
Why?
| | Transduction, Genetic | 5 | 2008 | 132 | 0.390 |
Why?
| | Viral Envelope Proteins | 1 | 2014 | 98 | 0.380 |
Why?
| | Glaucoma | 2 | 2009 | 247 | 0.380 |
Why?
| | Animals, Genetically Modified | 2 | 2011 | 245 | 0.370 |
Why?
| | Molecular Chaperones | 1 | 2014 | 182 | 0.360 |
Why?
| | Lentiviruses, Feline | 1 | 2011 | 1 | 0.350 |
Why?
| | Carnivora | 1 | 2011 | 6 | 0.340 |
Why?
| | Primate Diseases | 1 | 2011 | 8 | 0.340 |
Why?
| | Transfection | 7 | 2012 | 925 | 0.340 |
Why?
| | Intraocular Pressure | 3 | 2009 | 326 | 0.340 |
Why?
| | Base Sequence | 11 | 2012 | 2180 | 0.340 |
Why?
| | Cells, Cultured | 10 | 2012 | 4127 | 0.340 |
Why?
| | Monkey Diseases | 1 | 2011 | 25 | 0.340 |
Why?
| | Nuclear Localization Signals | 3 | 2006 | 16 | 0.340 |
Why?
| | Open Reading Frames | 1 | 2012 | 131 | 0.340 |
Why?
| | Mutation | 9 | 2020 | 4093 | 0.330 |
Why?
| | Gene Expression | 9 | 2013 | 1478 | 0.320 |
Why?
| | Green Fluorescent Proteins | 7 | 2011 | 407 | 0.320 |
Why?
| | Gene Products, vif | 1 | 2010 | 2 | 0.320 |
Why?
| | Antigens, CD | 1 | 2014 | 557 | 0.320 |
Why?
| | Nerve Tissue Proteins | 1 | 2014 | 590 | 0.320 |
Why?
| | Cell Nucleus | 5 | 2021 | 593 | 0.320 |
Why?
| | Luminescent Proteins | 4 | 2012 | 186 | 0.320 |
Why?
| | Cytidine Deaminase | 1 | 2010 | 59 | 0.310 |
Why?
| | Active Transport, Cell Nucleus | 6 | 2022 | 120 | 0.310 |
Why?
| | DNA Viruses | 1 | 2009 | 23 | 0.300 |
Why?
| | Prostaglandins | 1 | 2009 | 94 | 0.300 |
Why?
| | Purines | 1 | 2010 | 187 | 0.300 |
Why?
| | Eye Proteins | 4 | 2014 | 85 | 0.290 |
Why?
| | Disease Models, Animal | 5 | 2013 | 4559 | 0.290 |
Why?
| | Gene Knockdown Techniques | 2 | 2016 | 335 | 0.290 |
Why?
| | beta-Galactosidase | 3 | 2004 | 76 | 0.290 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1953 | 0.290 |
Why?
| | Cytoplasm | 5 | 2021 | 257 | 0.270 |
Why?
| | HIV-2 | 5 | 2002 | 18 | 0.270 |
Why?
| | RNA, Messenger | 5 | 2023 | 2820 | 0.270 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2009 | 153 | 0.270 |
Why?
| | Primates | 3 | 2020 | 133 | 0.260 |
Why?
| | Biological Evolution | 1 | 2011 | 488 | 0.260 |
Why?
| | HEK293 Cells | 5 | 2020 | 743 | 0.250 |
Why?
| | Retina | 3 | 2004 | 321 | 0.240 |
Why?
| | Gene Targeting | 2 | 2004 | 80 | 0.240 |
Why?
| | Antiviral Agents | 3 | 2022 | 772 | 0.240 |
Why?
| | Mice, Transgenic | 3 | 2020 | 2189 | 0.230 |
Why?
| | DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 8 | 0.230 |
Why?
| | Mice, Knockout | 4 | 2025 | 3125 | 0.230 |
Why?
| | Protein Binding | 8 | 2021 | 2250 | 0.220 |
Why?
| | Proteins | 3 | 2007 | 1020 | 0.220 |
Why?
| | Oncogenic Viruses | 1 | 2004 | 3 | 0.220 |
Why?
| | Genes, Reporter | 4 | 2012 | 276 | 0.210 |
Why?
| | HeLa Cells | 7 | 2020 | 633 | 0.210 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 975 | 0.210 |
Why?
| | Lymphocytes | 4 | 2012 | 379 | 0.200 |
Why?
| | Terminal Repeat Sequences | 2 | 2020 | 17 | 0.200 |
Why?
| | Cell Culture Techniques | 3 | 2012 | 373 | 0.200 |
Why?
| | Pigment Epithelium of Eye | 1 | 2003 | 36 | 0.200 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1996 | 237 | 0.200 |
Why?
| | Anti-HIV Agents | 2 | 2022 | 908 | 0.200 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 850 | 0.200 |
Why?
| | Anti-Retroviral Agents | 1 | 2005 | 251 | 0.200 |
Why?
| | Emigration and Immigration | 2 | 2020 | 66 | 0.200 |
Why?
| | Genome, Viral | 5 | 2019 | 218 | 0.200 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2023 | 6 | 0.190 |
Why?
| | Bone Marrow Stromal Antigen 2 | 1 | 2023 | 11 | 0.190 |
Why?
| | Protein Sorting Signals | 1 | 2023 | 21 | 0.190 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2023 | 27 | 0.190 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 130 | 0.190 |
Why?
| | Evolution, Molecular | 3 | 2020 | 518 | 0.190 |
Why?
| | RNA, Catalytic | 5 | 1998 | 191 | 0.190 |
Why?
| | Amino Acids | 2 | 2023 | 521 | 0.190 |
Why?
| | Caveolins | 1 | 2002 | 5 | 0.190 |
Why?
| | GPI-Linked Proteins | 1 | 2023 | 81 | 0.190 |
Why?
| | Mutation, Missense | 2 | 2014 | 338 | 0.190 |
Why?
| | Paragonimiasis | 1 | 2002 | 2 | 0.190 |
Why?
| | Paragonimus | 1 | 2002 | 2 | 0.190 |
Why?
| | Cytoskeletal Proteins | 3 | 2008 | 156 | 0.180 |
Why?
| | RNA, Small Interfering | 2 | 2020 | 632 | 0.180 |
Why?
| | Karyopherins | 2 | 2012 | 20 | 0.180 |
Why?
| | Genetic Engineering | 1 | 2003 | 89 | 0.180 |
Why?
| | Endemic Diseases | 1 | 2002 | 33 | 0.180 |
Why?
| | Gene Products, env | 3 | 2012 | 7 | 0.180 |
Why?
| | Aotidae | 2 | 2020 | 10 | 0.180 |
Why?
| | Virus Cultivation | 2 | 2012 | 31 | 0.180 |
Why?
| | Tripartite Motif Proteins | 2 | 2020 | 39 | 0.180 |
Why?
| | Saliva | 1 | 2023 | 247 | 0.170 |
Why?
| | Cytomegalovirus | 3 | 2012 | 168 | 0.170 |
Why?
| | Promoter Regions, Genetic | 4 | 2012 | 1247 | 0.170 |
Why?
| | Dogs | 2 | 2014 | 438 | 0.170 |
Why?
| | Glycoproteins | 3 | 2008 | 353 | 0.170 |
Why?
| | Genes, Viral | 2 | 2015 | 89 | 0.160 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2012 | 207 | 0.160 |
Why?
| | Cyclophilin A | 1 | 2020 | 27 | 0.160 |
Why?
| | Viral Proteins | 3 | 2015 | 353 | 0.160 |
Why?
| | 3T3 Cells | 1 | 2020 | 156 | 0.160 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 7 | 0.160 |
Why?
| | Immunologic Surveillance | 1 | 2020 | 25 | 0.160 |
Why?
| | Vesicular Transport Proteins | 1 | 2021 | 85 | 0.160 |
Why?
| | Plasmids | 5 | 2012 | 375 | 0.160 |
Why?
| | Disease Resistance | 1 | 2020 | 29 | 0.160 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 5 | 0.160 |
Why?
| | Drug Resistance, Viral | 2 | 2014 | 124 | 0.160 |
Why?
| | Quarantine | 1 | 2020 | 31 | 0.160 |
Why?
| | Growth Inhibitors | 2 | 2013 | 39 | 0.150 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2020 | 35 | 0.150 |
Why?
| | Immunoassay | 1 | 2020 | 108 | 0.150 |
Why?
| | Immune Evasion | 1 | 2020 | 62 | 0.150 |
Why?
| | RNA Virus Infections | 1 | 2019 | 20 | 0.150 |
Why?
| | Interferon-beta | 1 | 2020 | 92 | 0.150 |
Why?
| | Immunoblotting | 2 | 2014 | 294 | 0.150 |
Why?
| | Endogenous Retroviruses | 1 | 2020 | 37 | 0.150 |
Why?
| | Vancomycin | 1 | 2020 | 94 | 0.150 |
Why?
| | Immunity, Humoral | 1 | 2020 | 120 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 187 | 0.150 |
Why?
| | Ciliary Body | 2 | 2009 | 40 | 0.150 |
Why?
| | Embryonic Development | 1 | 2020 | 125 | 0.150 |
Why?
| | Interferon Type I | 1 | 2020 | 147 | 0.140 |
Why?
| | Viremia | 1 | 2020 | 160 | 0.140 |
Why?
| | Sequence Alignment | 2 | 2014 | 371 | 0.140 |
Why?
| | Afghanistan | 1 | 2019 | 96 | 0.140 |
Why?
| | Cell Transformation, Viral | 1 | 1998 | 23 | 0.140 |
Why?
| | Monocytes | 2 | 2018 | 536 | 0.140 |
Why?
| | THP-1 Cells | 1 | 2018 | 20 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 907 | 0.140 |
Why?
| | RNA Viruses | 1 | 2019 | 76 | 0.140 |
Why?
| | Receptors, CXCR4 | 1 | 1998 | 91 | 0.130 |
Why?
| | Transcription, Genetic | 4 | 2016 | 1468 | 0.130 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 158 | 0.130 |
Why?
| | Genes, vif | 2 | 2010 | 3 | 0.130 |
Why?
| | Renal Insufficiency | 1 | 2020 | 172 | 0.130 |
Why?
| | Protein Transport | 2 | 2012 | 438 | 0.130 |
Why?
| | Residence Characteristics | 1 | 2020 | 376 | 0.130 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2020 | 239 | 0.130 |
Why?
| | T-Lymphocytes | 5 | 2020 | 1996 | 0.130 |
Why?
| | Rats | 7 | 2014 | 5581 | 0.130 |
Why?
| | Genes, Immediate-Early | 2 | 2012 | 26 | 0.120 |
Why?
| | Quinolines | 2 | 2014 | 193 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 452 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 553 | 0.120 |
Why?
| | Kinetics | 6 | 2013 | 1605 | 0.120 |
Why?
| | Blotting, Western | 5 | 2015 | 1162 | 0.110 |
Why?
| | Public Health | 1 | 2020 | 573 | 0.110 |
Why?
| | Species Specificity | 2 | 2012 | 573 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 672 | 0.110 |
Why?
| | Echinocandins | 1 | 2014 | 8 | 0.110 |
Why?
| | Gene Products, rev | 2 | 2004 | 6 | 0.110 |
Why?
| | Mucormycosis | 1 | 2014 | 18 | 0.110 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2014 | 76 | 0.110 |
Why?
| | Amphotericin B | 1 | 2014 | 36 | 0.110 |
Why?
| | Acetates | 1 | 2014 | 81 | 0.100 |
Why?
| | Voriconazole | 1 | 2014 | 21 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2594 | 0.100 |
Why?
| | Organ Culture Techniques | 3 | 2006 | 149 | 0.100 |
Why?
| | Sequence Deletion | 2 | 2006 | 191 | 0.100 |
Why?
| | Genes, gag | 2 | 2004 | 4 | 0.100 |
Why?
| | Ocular Hypertension | 1 | 2014 | 67 | 0.100 |
Why?
| | Cyclophilins | 1 | 2014 | 40 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1049 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2020 | 739 | 0.100 |
Why?
| | Female | 15 | 2020 | 78763 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 150 | 0.100 |
Why?
| | Introns | 3 | 2015 | 256 | 0.100 |
Why?
| | Retroviridae Proteins | 2 | 2012 | 10 | 0.100 |
Why?
| | Protein Multimerization | 1 | 2014 | 207 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 4 | 2014 | 2526 | 0.090 |
Why?
| | Vero Cells | 2 | 2019 | 84 | 0.090 |
Why?
| | F-Box Proteins | 1 | 2012 | 23 | 0.090 |
Why?
| | Microscopy, Confocal | 2 | 2004 | 318 | 0.090 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 10 | 0.090 |
Why?
| | DNA-Binding Proteins | 3 | 2013 | 1487 | 0.090 |
Why?
| | Genes, env | 1 | 2012 | 5 | 0.090 |
Why?
| | Genes, Synthetic | 1 | 2012 | 14 | 0.090 |
Why?
| | Collagen | 1 | 2014 | 453 | 0.090 |
Why?
| | Mink | 1 | 2011 | 12 | 0.090 |
Why?
| | Rabbits | 2 | 2011 | 651 | 0.090 |
Why?
| | Feline Acquired Immunodeficiency Syndrome | 1 | 2011 | 2 | 0.090 |
Why?
| | bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 14 | 0.090 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 272 | 0.090 |
Why?
| | Caspase 8 | 1 | 2011 | 47 | 0.090 |
Why?
| | DNA | 3 | 2005 | 1451 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 5989 | 0.090 |
Why?
| | bcl-2-Associated X Protein | 1 | 2011 | 52 | 0.080 |
Why?
| | Histidine | 2 | 2014 | 65 | 0.080 |
Why?
| | Jurkat Cells | 3 | 2020 | 115 | 0.080 |
Why?
| | Male | 13 | 2020 | 72817 | 0.080 |
Why?
| | APOBEC-3G Deaminase | 1 | 2010 | 5 | 0.080 |
Why?
| | Signal Transduction | 2 | 2020 | 5202 | 0.080 |
Why?
| | vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 3 | 0.080 |
Why?
| | Macrophages | 3 | 2009 | 1509 | 0.080 |
Why?
| | Injections | 2 | 2009 | 200 | 0.080 |
Why?
| | Virus Internalization | 1 | 2010 | 65 | 0.080 |
Why?
| | Polyradiculoneuropathy | 1 | 2009 | 5 | 0.080 |
Why?
| | Swine | 2 | 2009 | 833 | 0.070 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2009 | 31 | 0.070 |
Why?
| | Isoenzymes | 1 | 2010 | 297 | 0.070 |
Why?
| | Iris | 1 | 2009 | 23 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2009 | 166 | 0.070 |
Why?
| | Macaca fascicularis | 1 | 2009 | 70 | 0.070 |
Why?
| | Gene Deletion | 2 | 2002 | 392 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2008 | 25 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 2 | 2004 | 468 | 0.070 |
Why?
| | Endosomes | 1 | 2010 | 140 | 0.070 |
Why?
| | Recombinant Proteins | 2 | 2009 | 1367 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2009 | 182 | 0.070 |
Why?
| | Young Adult | 4 | 2020 | 14192 | 0.070 |
Why?
| | Cell Division | 2 | 2001 | 753 | 0.070 |
Why?
| | Neoplasms | 2 | 2013 | 2897 | 0.070 |
Why?
| | Saccharomyces cerevisiae | 1 | 2013 | 580 | 0.070 |
Why?
| | Infectious Anemia Virus, Equine | 1 | 2007 | 1 | 0.070 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 2 | 2004 | 6 | 0.070 |
Why?
| | RNA Splicing | 2 | 2015 | 286 | 0.070 |
Why?
| | Occupational Diseases | 1 | 2009 | 165 | 0.070 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2007 | 191 | 0.070 |
Why?
| | Glaucoma, Open-Angle | 1 | 2009 | 104 | 0.070 |
Why?
| | Cell Membrane | 3 | 2010 | 707 | 0.070 |
Why?
| | Antigens, CD34 | 2 | 1998 | 89 | 0.060 |
Why?
| | United States | 3 | 2020 | 16115 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2010 | 573 | 0.060 |
Why?
| | Models, Genetic | 1 | 2009 | 531 | 0.060 |
Why?
| | Gene Products, pol | 2 | 1998 | 6 | 0.060 |
Why?
| | Phylogeny | 1 | 2011 | 1028 | 0.060 |
Why?
| | Virulence | 1 | 2007 | 282 | 0.060 |
Why?
| | Defective Viruses | 2 | 2004 | 5 | 0.060 |
Why?
| | Crystallography, X-Ray | 2 | 2020 | 491 | 0.060 |
Why?
| | Binding Sites | 2 | 2021 | 1313 | 0.060 |
Why?
| | Chromosomes, Human | 1 | 2006 | 41 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2012 | 1350 | 0.060 |
Why?
| | Occupational Exposure | 1 | 2009 | 355 | 0.060 |
Why?
| | Retinal Ganglion Cells | 2 | 2004 | 117 | 0.060 |
Why?
| | Time Factors | 2 | 2009 | 7171 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1094 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 780 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2009 | 693 | 0.060 |
Why?
| | Avian Leukosis Virus | 1 | 2005 | 6 | 0.060 |
Why?
| | Models, Biological | 1 | 2013 | 1815 | 0.060 |
Why?
| | Genes, Regulator | 1 | 2005 | 35 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 366 | 0.060 |
Why?
| | Leukemia Virus, Gibbon Ape | 1 | 2005 | 1 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2005 | 147 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2004 | 38 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2006 | 279 | 0.050 |
Why?
| | Ribonucleases | 1 | 2004 | 49 | 0.050 |
Why?
| | Indicators and Reagents | 1 | 2004 | 106 | 0.050 |
Why?
| | Immunoprecipitation | 1 | 2004 | 147 | 0.050 |
Why?
| | Ubiquitin | 1 | 2004 | 83 | 0.050 |
Why?
| | Mitochondria | 1 | 2011 | 990 | 0.050 |
Why?
| | Genes, vpu | 1 | 2004 | 1 | 0.050 |
Why?
| | Aged | 6 | 2020 | 26125 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2009 | 743 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 2 | 1998 | 419 | 0.050 |
Why?
| | Protease Inhibitors | 1 | 2004 | 101 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2355 | 0.050 |
Why?
| | Histones | 1 | 2009 | 663 | 0.050 |
Why?
| | Digestive System Diseases | 1 | 2003 | 28 | 0.050 |
Why?
| | Models, Molecular | 2 | 2022 | 1614 | 0.050 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2004 | 94 | 0.050 |
Why?
| | Alleles | 2 | 2020 | 893 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2007 | 733 | 0.050 |
Why?
| | Adenoviridae | 1 | 2004 | 199 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 407 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2004 | 268 | 0.050 |
Why?
| | Codon, Initiator | 1 | 2002 | 11 | 0.050 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| | Virus Uncoating | 1 | 2022 | 1 | 0.050 |
Why?
| | Proviruses | 1 | 2002 | 16 | 0.050 |
Why?
| | Caveolin 1 | 1 | 2002 | 20 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2411 | 0.050 |
Why?
| | Laos | 1 | 2002 | 3 | 0.050 |
Why?
| | Eye Diseases | 1 | 2003 | 95 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2002 | 199 | 0.050 |
Why?
| | Aphidicolin | 1 | 2001 | 5 | 0.040 |
Why?
| | Leukemia Virus, Murine | 1 | 2001 | 17 | 0.040 |
Why?
| | Cell Cycle | 1 | 2005 | 595 | 0.040 |
Why?
| | Respiratory Tract Diseases | 1 | 2003 | 176 | 0.040 |
Why?
| | Lac Operon | 1 | 2001 | 44 | 0.040 |
Why?
| | Genetic Markers | 1 | 2002 | 334 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2022 | 93 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2002 | 364 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2002 | 509 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2022 | 235 | 0.040 |
Why?
| | Nuclear Pore | 1 | 2021 | 18 | 0.040 |
Why?
| | Osteoblasts | 1 | 2002 | 146 | 0.040 |
Why?
| | Organ Specificity | 1 | 2001 | 312 | 0.040 |
Why?
| | Deuterium Exchange Measurement | 1 | 2020 | 27 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 1040 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2021 | 220 | 0.040 |
Why?
| | Nervous System Diseases | 1 | 2003 | 287 | 0.040 |
Why?
| | Phenotype | 2 | 2013 | 3157 | 0.040 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2020 | 3 | 0.040 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 16 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2020 | 186 | 0.040 |
Why?
| | HCT116 Cells | 1 | 2020 | 78 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2373 | 0.040 |
Why?
| | Middle Aged | 6 | 2020 | 36176 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 567 | 0.040 |
Why?
| | Travel | 1 | 2020 | 136 | 0.040 |
Why?
| | Proteinuria | 1 | 2020 | 104 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1710 | 0.040 |
Why?
| | Nucleic Acid Conformation | 1 | 2002 | 729 | 0.040 |
Why?
| | Cryoelectron Microscopy | 1 | 2020 | 222 | 0.040 |
Why?
| | Sheep | 1 | 2022 | 882 | 0.040 |
Why?
| | Horses | 1 | 2020 | 227 | 0.040 |
Why?
| | Neurons | 2 | 1998 | 1647 | 0.040 |
Why?
| | Protein Domains | 1 | 2020 | 314 | 0.040 |
Why?
| | Giant Cells | 1 | 1998 | 21 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2001 | 831 | 0.030 |
Why?
| | Rodentia | 1 | 1998 | 62 | 0.030 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1998 | 35 | 0.030 |
Why?
| | Cattle | 1 | 2020 | 977 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2014 | 1046 | 0.030 |
Why?
| | Needs Assessment | 1 | 2020 | 401 | 0.030 |
Why?
| | Coculture Techniques | 1 | 1998 | 246 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1998 | 117 | 0.030 |
Why?
| | Mutagenesis | 1 | 1998 | 194 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2008 | 8326 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2020 | 321 | 0.030 |
Why?
| | Brain | 1 | 2009 | 2944 | 0.030 |
Why?
| | Age Factors | 1 | 2003 | 3340 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2020 | 673 | 0.030 |
Why?
| | RNA | 1 | 2022 | 929 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1507 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2015 | 318 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 667 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 1995 | 53 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2014 | 104 | 0.030 |
Why?
| | Receptors, Purinergic | 3 | 1990 | 20 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2013 | 3537 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 339 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 303 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 751 | 0.020 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 2013 | 13 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 839 | 0.020 |
Why?
| | History, 21st Century | 1 | 2014 | 220 | 0.020 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2013 | 26 | 0.020 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2013 | 47 | 0.020 |
Why?
| | Virus Diseases | 1 | 2015 | 218 | 0.020 |
Why?
| | Galactose | 1 | 2013 | 32 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 113 | 0.020 |
Why?
| | Tumor Escape | 1 | 2013 | 50 | 0.020 |
Why?
| | Gene Library | 1 | 2013 | 124 | 0.020 |
Why?
| | Succinate Dehydrogenase | 1 | 2013 | 66 | 0.020 |
Why?
| | Fungi | 1 | 2014 | 161 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2012 | 156 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 139 | 0.020 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2012 | 27 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 196 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2012 | 147 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4283 | 0.020 |
Why?
| | Receptors, Cell Surface | 2 | 1984 | 372 | 0.020 |
Why?
| | Paraganglioma | 1 | 2013 | 64 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 507 | 0.020 |
Why?
| | Protein Conformation | 1 | 2014 | 935 | 0.020 |
Why?
| | Immunotherapy | 2 | 2013 | 667 | 0.020 |
Why?
| | Caspase 9 | 1 | 2011 | 51 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2003 | 2185 | 0.020 |
Why?
| | Epitopes | 1 | 2013 | 480 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1995 | 342 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 398 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3759 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2011 | 413 | 0.020 |
Why?
| | Adenosine | 2 | 1990 | 256 | 0.020 |
Why?
| | Salt Gland | 1 | 1990 | 1 | 0.020 |
Why?
| | Abattoirs | 1 | 2009 | 3 | 0.020 |
Why?
| | Myelin Basic Protein | 1 | 2009 | 44 | 0.020 |
Why?
| | Indiana | 1 | 2009 | 38 | 0.020 |
Why?
| | Adipose Tissue | 2 | 1984 | 644 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1142 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4572 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1995 | 1058 | 0.020 |
Why?
| | Cyclic AMP | 1 | 1990 | 207 | 0.020 |
Why?
| | Air Pollutants, Occupational | 1 | 2009 | 41 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 821 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2013 | 579 | 0.020 |
Why?
| | Chlorides | 1 | 1990 | 142 | 0.020 |
Why?
| | Minnesota | 1 | 2009 | 170 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2009 | 84 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 430 | 0.020 |
Why?
| | Inhalation Exposure | 1 | 2009 | 103 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2008 | 41 | 0.020 |
Why?
| | Aerosols | 1 | 2009 | 188 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 631 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 112 | 0.020 |
Why?
| | Hybridomas | 1 | 2008 | 233 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2008 | 178 | 0.020 |
Why?
| | Consensus Sequence | 1 | 2007 | 73 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 881 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 5426 | 0.020 |
Why?
| | Adult | 3 | 2020 | 40707 | 0.020 |
Why?
| | Eye | 1 | 2008 | 112 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1156 | 0.020 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2006 | 10 | 0.020 |
Why?
| | Melanoma | 1 | 2013 | 759 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2009 | 426 | 0.010 |
Why?
| | HIV Protease Inhibitors | 1 | 2006 | 69 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 978 | 0.010 |
Why?
| | Microarray Analysis | 1 | 2005 | 116 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2008 | 1261 | 0.010 |
Why?
| | Treatment Failure | 1 | 2006 | 365 | 0.010 |
Why?
| | Ethylmaleimide | 1 | 1984 | 18 | 0.010 |
Why?
| | Gene Silencing | 1 | 2005 | 202 | 0.010 |
Why?
| | Clinical Protocols | 2 | 1998 | 282 | 0.010 |
Why?
| | Guanine Nucleotides | 1 | 1984 | 12 | 0.010 |
Why?
| | Codon | 1 | 2004 | 93 | 0.010 |
Why?
| | PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2002 | 1 | 0.010 |
Why?
| | Hypophosphatemia, Familial | 1 | 2002 | 4 | 0.010 |
Why?
| | Autoantibodies | 1 | 2009 | 1512 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2030 | 0.010 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2002 | 29 | 0.010 |
Why?
| | Growth Plate | 1 | 2002 | 39 | 0.010 |
Why?
| | Golgi Apparatus | 1 | 2002 | 99 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2002 | 396 | 0.010 |
Why?
| | Vitreous Body | 1 | 2002 | 117 | 0.010 |
Why?
| | Blood Platelets | 1 | 1984 | 380 | 0.010 |
Why?
| | Skull | 1 | 2002 | 161 | 0.010 |
Why?
| | In Vitro Techniques | 3 | 1990 | 1047 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22485 | 0.010 |
Why?
| | Endoplasmic Reticulum | 1 | 2002 | 264 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2002 | 890 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 1998 | 20 | 0.010 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 1998 | 50 | 0.010 |
Why?
| | Adenylyl Cyclases | 2 | 1990 | 60 | 0.010 |
Why?
| | Skin | 1 | 2002 | 766 | 0.010 |
Why?
| | Phenylisopropyladenosine | 2 | 1984 | 3 | 0.010 |
Why?
| | Hydrolysis | 1 | 1995 | 199 | 0.010 |
Why?
| | Gentamicins | 1 | 1994 | 50 | 0.010 |
Why?
| | RNA Polymerase III | 1 | 1994 | 34 | 0.010 |
Why?
| | RNA, Antisense | 1 | 1994 | 18 | 0.010 |
Why?
| | Drug Resistance | 1 | 1994 | 146 | 0.010 |
Why?
| | Selection, Genetic | 1 | 1994 | 258 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2006 | 11831 | 0.010 |
Why?
| | 2-Chloroadenosine | 1 | 1990 | 3 | 0.010 |
Why?
| | Dogfish | 1 | 1990 | 4 | 0.000 |
Why?
| | Colforsin | 1 | 1990 | 47 | 0.000 |
Why?
| | Theophylline | 1 | 1990 | 41 | 0.000 |
Why?
| | Somatostatin | 1 | 1990 | 53 | 0.000 |
Why?
| | Perfusion | 1 | 1990 | 249 | 0.000 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1994 | 700 | 0.000 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 1984 | 9 | 0.000 |
Why?
| | Xanthines | 1 | 1984 | 23 | 0.000 |
Why?
| | Radioligand Assay | 1 | 1984 | 36 | 0.000 |
Why?
| | Tritium | 1 | 1984 | 68 | 0.000 |
Why?
| | Guanosine Triphosphate | 1 | 1984 | 89 | 0.000 |
Why?
| | Magnesium | 1 | 1984 | 156 | 0.000 |
Why?
| | Sodium | 1 | 1984 | 198 | 0.000 |
Why?
| | Vasodilator Agents | 1 | 1984 | 330 | 0.000 |
Why?
| | Calcium | 1 | 1984 | 1190 | 0.000 |
Why?
|
|
Poeschla's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|